Hyclone Life Sciences Solutions India Profile
Key Indicators
- Authorised Capital ₹ 245.00 Cr
as on 16-06-2024
- Paid Up Capital ₹ 235.16 Cr
as on 16-06-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2.70%
(FY 2023)
- Profit -20.38%
(FY 2023)
- Ebitda -23.88%
(FY 2023)
- Net Worth 38.95%
(FY 2023)
- Total Assets 17.73%
(FY 2023)
About Hyclone Life Sciences Solutions India
The Company is engaged in the Life Science Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 245.00 Cr and a paid-up capital of Rs 235.16 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Hyclone Life Sciences Solutions India Private Limited India is Amol Kulkarni as COMPANY SECRETARY. James Benjamin, Sankaran Rajan, and Satya Udandravu serve as directors at the Company.
- CIN/LLPIN
U24304KA2019PTC126720
- Company No.
126720
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Hyclone Life Sciences Solutions India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amol Kulkarni  | Company Secretary | 06-Mar-2020 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satya Udandravu | Director | 14-Jun-2022 | Current |
| James Benjamin | Director | 31-Mar-2020 | Current |
| Sankaran Rajan | Director | 08-Nov-2022 | Current |
Financial Performance and Corporate Structure Insights of Hyclone Life Sciences Solutions India.
Hyclone Life Sciences Solutions India Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.7% increase. The company also saw a substantial fall in profitability, with a 20.38% decrease in profit. The company's net worth Soared by an impressive increase of 38.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hyclone Life Sciences Solutions India?
In 2023, Hyclone Life Sciences Solutions India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
2 years 5 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hyclone Life Sciences Solutions India?
Hyclone Life Sciences Solutions India has a workforce of 496 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Jan 29, 2020, Hyclone Life Sciences Solutions India has raised a total of ₹ 470.31 Cr, with the most recent deal valued at ₹ 235.15 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
